Trial · NCT00782288
Results by group190
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 190
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Placebo | IL-8 Day 1 | 4.59 | Inter-Quartile Range 4.15 to 5.12 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Low Dose 0.05 mg Digitoxin | IL-8 Day 1 | 4.96 | Inter-Quartile Range 4.4 to 5.18 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Higher Dose 0.1mg Digitoxin | IL-8 Day 1 | 5.04 | Inter-Quartile Range 4.58 to 5.10 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Placebo | IL-8 Day 14 | 4.94 | Inter-Quartile Range 4.21 to 5.34 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Low Dose 0.05 mg Digitoxin | IL-8 Day 14 | 4.89 | Inter-Quartile Range 4.50 to 5.01 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Higher Dose 0.1mg Digitoxin | IL-8 Day 14 | 5.01 | Inter-Quartile Range 4.66 to 5.45 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Placebo | IL-8 Day 21 | 5.08 | Inter-Quartile Range 4.21 to 5.38 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Low Dose 0.05 mg Digitoxin | IL-8 Day 21 | 4.77 | Inter-Quartile Range 4.64 to 4.89 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Higher Dose 0.1mg Digitoxin | IL-8 Day 21 | 5.17 | Inter-Quartile Range 4.66 to 5.42 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Placebo | IL-8 Day 28 | 4.66 | Inter-Quartile Range 4.49 to 5.38 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Low Dose 0.05 mg Digitoxin | IL-8 Day 28 | 4.79 | Inter-Quartile Range 4.49 to 4.91 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Higher Dose 0.1mg Digitoxin | IL-8 Day 28 | 5.20 | Inter-Quartile Range 4.68 to 5.34 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Placebo | IL-8 Day 42 | 4.59 | Inter-Quartile Range 4.22 to 5.06 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Low Dose 0.05 mg Digitoxin | IL-8 Day 42 | 4.74 | Inter-Quartile Range 4.62 to 5.04 | log 10 (pg/mL) |
| Effect of Digitoxin on IL-8 (Interleukin 8) in Induced Sputum in Stable Cystic Fibrosis (CF) Patients. | Higher Dose 0.1mg Digitoxin | IL-8 Day 42 | 4.97 | Inter-Quartile Range 4.43 to 5.25 | log 10 (pg/mL) |
| Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients. | Placebo | Day 7, digitoxin level 5.6 ng/mL | 0 | participants | |
| Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients. | Low Dose 0.05mg Digitoxin | Day 7, digitoxin level 5.6 ng/mL | 0 | participants | |
| Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients. | Higher Dose 0.1mg Digitoxin | Day 7, digitoxin level 5.6 ng/mL | 1 | participants | |
| Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients. | Placebo | Day 7, digitoxin level 6 ng/mL | 0 | participants | |
| Pharmacokinetics (PK) of Digitoxin in Serum in Stable CF Patients. | Low Dose 0.05mg Digitoxin | Day 7, digitoxin level 6 ng/mL | 1 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00782288/results